|

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

RECRUITINGPhase 4Sponsored by Gangnam Severance Hospital
Actively Recruiting
PhasePhase 4
SponsorGangnam Severance Hospital
Started2023-02-06
Est. completion2031-01
Eligibility
Age20 Years – 50 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05333328

Summary

Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.

Eligibility

Age: 20 Years – 50 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* ER+HER2- breast cancer
* Premenopausal and age \<=50
* T1 or T2
* N1 including micrometastasis
* Genomic Low Risk by OncoFREE test® (1-20)

Exclusion Criteria:

* Postmenopausal women
* ER-negative breast cancer

Conditions6

Breast CancerCancerEstrogen Receptor Positive TumorHER2-negative Breast CancerNode-positive Breast CancerPremenopausal Breast Cancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.